AZ’s EGPA drug Fasenra receives orphan drug designation
By Eo, Yun-Ho | translator Kim, Jung-Ju
24.03.10 13:41:54
가나다라
0
Presented results of the MANDARA trial at the American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
The head-to-head trial directly compared the drug with GSK’s antibody drug Nucala and demonstrated non-inferiority
AstraZeneca's antibody drug Fasenra has been designated as an orphan drug in Korea for its eosinophilic granulomatosis indication.
The Ministry of Food and Drug Safety announced so through an official orphan drug designation notice on the 7th. More specifically, the drug received an orphan drug designation as a treatment for eosinophilic granulomatosis with polyangiitis (EGPA)
Fasenra (benralizumab)’s EGPA indication was granted an orphan drug designation by the US FDA in 2018.
AstraZeneca recently presented results from its MANDARA trial at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, showing the drug’s potential. The MANDARA tr
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)